Cellectis, CiRA Partner on Induced Pluripotent Stem Cell Technology Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French genome engineering firm Cellectis and the Center for iPS Cells Research and Application of Kyoto University today announced a collaboration to combine their technologies to develop induced pluripotent stem cells, or iPS, as cellular tools.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.